RE: Anyone buying at this level?1 Feb 2026 12:12
The AIM market is in a far healthier place than it has been for years. In early 2024 a number of factors came together to cause the 50p raise - management simply hadn't planned for it because the deal that was being worked at the back end of 2023 fell through, secondly we were still limping along with cohort after cohort in 1a in a drug that at best was likely to be approved for a couple of relatively niche indications and in addition the lack of liquidity in small caps meant raising such a large sum of cash was challenging to say the least. And yet still it was considered such a failure as to drive Alastair, the company founder, out of the business.
Anyone that thinks Avacta under Christina and Richard's guidance, well through 1b and with the first patient dosed in ava6103 (a drug with a far, far greater addressable market) is going to end up raising below that failure of a 2024 raise isn't a savvy investor or trader.